All News
Filter News
Found 46,731 articles
-
Ascential Medical & Life Sciences Appoints Anupam Girdhar as Divisional CEO
4/16/2024
Ascential Medical & Life Sciences announced the appointment of Anupam Girdhar as divisional CEO. A business leader with 25 years of operational and strategic experience, Mr. Girdhar has managed complex life science tools and medical devices businesses.
-
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock - April 16, 2024
4/16/2024
Intra-Cellular Therapies, Inc. announced that it has commenced an underwritten public offering of $500 million of shares of its common stock.
-
Faron Confirms Plans for the Coming Months Under New Leadership - April 16, 2024
4/16/2024
Faron Pharmaceuticals Ltd. announces ongoing plans and activities for the coming months following the recent announcement of the proposed appointment of Dr. Juho Jalkanen as Chief Executive Officer, effective 1 May 2024.
-
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
4/16/2024
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Bob Dagher to Executive Vice President and Chief Medical Officer.
-
CVRx announces availability of additional data supporting long-term benefits of Barostim
4/15/2024
CVRx, Inc., a commercial-stage medical device company, announced the availability of additional data, including the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure.
-
Robotic Cataract Surgery Using ForSight Robotics’ ORYOMTM Platform Presented For the First Time at the ASCRS Annual Meeting
4/15/2024
Dr. David F. Chang, 2024 Kelman Innovator Lecturer, Presented the Cataract Surgery Robotics Platform at ASCRS Conference
-
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
4/15/2024
TransCode Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has completed its review of the company’s Investigational New Drug (IND) application and concluded that the company may proceed with its Phase 1/2 multicenter, open-label, dose-escalation and dose-expansion study of its lead therapeutic candidate.
-
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
4/15/2024
Ultragenyx Pharmaceutical Inc. announced new data from the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome.
-
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
4/15/2024
Tharimmune, Inc. announced today the formation of a new Scientific Advisory Board (SAB).
-
BC Platforms and NTT Group Announce Official Opening Ceremony for Exclusive Collaboration and Launch of Japanese Precision Medicine Platform
4/15/2024
BC Platforms, a global leader in real world data, healthcare data management, and analytics, announces an exclusive collaboration with NTT Life Science Corporation, a company in the medical field of the NTT Group, to accelerate data-driven medicine.
-
BioBam Releases OmicsBox 3.2: Single Cell Transcriptomics Made Easy
4/15/2024
BioBam, a leading provider of bioinformatics solutions, is pleased to announce the launch of OmicsBox 3.2 at the BIO-IT World Expo in Boston.
-
Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
4/15/2024
Akari Therapeutics, Plc today announced the company will present new pre-clinical data on investigational long-acting PAS-nomacopan including drug effect on electroretinography (ERG) testing in a blue light model at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle.
-
Microbion Selected to Present at Advanced Wound Care Summit USA
4/15/2024
Microbion Corporation today announced that the company has been selected to present topical pravibismane for the treatment of diabetic foot infection (DFI) at the Advanced Wound Care Summit USA held at the Boston Marriot Long Wharf from April 16th to 17th.
-
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
4/12/2024
AbbVie (NYSE: ABBV) today announced an interim analysis of an ongoing Phase 3, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine.
-
Modalis Announces Partnership with Ginkgo Bioworks
4/12/2024
Modalis Therapeutics Corporation announced that it has entered into an agreement with Ginkgo Bioworks to join the Ginkgo Technology Network.
-
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
4/12/2024
Compass Therapeutics, Inc. today announced poster presentations on CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, at the Cholangiocarcinoma Foundation (CCF) 2024 Annual Conference to be held at the Salt Palace Convention Center in Salt Lake City, Utah from April 17–19, 2024.
-
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
4/12/2024
Praxis Precision Medicines, Inc. today announced that it will deliver presentations of two abstracts showcasing progress of its clinical program evaluating ulixacaltamide for adults with essential tremor (ET) at the American Academy of Neurology (AAN) 2024 Annual Meeting taking place in Denver, Colorado, April 13 – 18, 2024.
-
CND Life Sciences to Highlight Momentum of Skin Biopsy Diagnostic Tool for Parkinson’s Disease and Related Disorders at the American Academy of Neurology 2024 Annual Meeting
4/12/2024
CND Life Sciences today announced that six abstracts related to the identification of phosphorylated alpha-synuclein (P-SYN) in cutaneous nerve fibers in the skin will be presented at the American Academy of Neurology 2024 Annual Meeting (AAN) on April 13-18 in Denver at the Colorado Convention Center.
-
Seismic Therapeutic Presents Preclinical Data on S-1117, its Novel Pan-IgG Protease Addressing Multiple Pathogenic Mechanisms in Autoimmune Disease, at American Academy of Neurology (AAN) 2024
4/12/2024
Seismic Therapeutic, Inc today announced the presentation of preclinical data for its pan‑immunoglobulin G (IgG) sculpting enzyme candidate, S-1117, at the American Academy of Neurology (AAN) 2024 annual meeting in Denver.
-
Vertex Pharmaceuticals on Wednesday announced it is acquiring clinical-stage immunotherapy company Alpine Immune Sciences for $4.9 billion in cash, the largest acquisition so far this year.